Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity

Bibliography

• Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003;24(3):253-62
   PubMed Web of Science ®Google Scholar
• Johansson R, Hourihane J, Bousquet J, A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56(9):813-24
   PubMed Web of Science ®Google Scholar
• Syrigou E, Makrilia N, Koti I, Hypersensitivity reactions to antineoplastic agents: an overview. Anticancer Drugs 2009;20(1):1-6
   PubMed Web of Science ®Google Scholar
• Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12(5):601-9
   PubMed Web of Science ®Google Scholar
• Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008;13(6):725-32
   PubMed Web of Science ®Google Scholar
• Gobel BH. Chemotherapy-induced hypersensitivity reactions. Oncol Nurs Forum 2005;32(5):1027-35
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194-200
   PubMed Web of Science ®Google Scholar
• du Bois A, Luck HJ, Meier W, A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95(17):1320-9
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334(1):1-6
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361(9375):2099-106
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I, Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24(29):4699-707
   PubMed Web of Science ®Google Scholar
• Neijt JP, Engelholm SA, Tuxen MK, Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18(17):3084-92
   PubMed Web of Science ®Google Scholar
• Cleare MJ, Hughes EG, Jacoby B, Pepys J. Immediate (type I) allergic responses to platinum compounds. Clin Allergy 1976;6:183-95
   PubMedGoogle Scholar
• Shukunami K, Kurokawa T, Kawakami Y, Hypersensitivity reactions to intraperitoneal administration of carboplatin in ovarian cancer: the first report of a case. Gynecol Oncol 1999;72(3):431-2
   PubMed Web of Science ®Google Scholar
• Markman M, Kennedy A, Webster K, Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999;17(4):1141
   PubMed Web of Science ®Google Scholar
• Siu SW, Chan RT, Au GK. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 2006;17(2):259-61
   PubMed Web of Science ®Google Scholar
• Kim BH, Bradley T, Tai J, Budman DR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology 2009;76(4):231-8
   PubMed Web of Science ®Google Scholar
• Brandi G, Pantaleo MA, Galli C, Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003;89(3):477-81
   PubMed Web of Science ®Google Scholar
• Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer 2005;15(1):13-8
   PubMed Web of Science ®Google Scholar
• Polyzos A, Tsavaris N, Kosmas C, Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001;61(2):129-33
   PubMed Web of Science ®Google Scholar
• Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004;95(2):370-6
   PubMed Web of Science ®Google Scholar
• Gadducci A, Tana R, Teti G, Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008;18(4):615-20
   PubMed Web of Science ®Google Scholar
• Leguy-Seguin V, Jolimoy G, Coudert B, Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol 2007;119(3):726-30
   PubMed Web of Science ®Google Scholar
• Dizon DS, Sabbatini PJ, Aghajanian C, Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002;84(3):378-82
   PubMed Web of Science ®Google Scholar
• Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003;97(9):2301-7
   PubMed Web of Science ®Google Scholar
• Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 2005;96(3):824-9
   PubMed Web of Science ®Google Scholar
• Zanotti KM, Rybicki LA, Kennedy AW, Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001;19(12):3126-9
   PubMed Web of Science ®Google Scholar
• Markman M, Zanotti K, Peterson G, Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003;21(24):4611-4
   PubMed Web of Science ®Google Scholar
• Meyer L, Zuberbier T, Worm M, Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002;20(4):1146-7
   PubMed Web of Science ®Google Scholar
• Garufi C, Cristaudo A, Vanni B, Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 2003;14(3):497-8
   PubMed Web of Science ®Google Scholar
• Arbuck SG, Donehower RC. Proceedings of the Second National Cancer Institute Workshop on Taxol and Taxus. J Natl Cancer Inst 1993;15:131-9, 55-79
   Google Scholar
• Crown J, O'Leary M. The taxanes: an update. Lancet 2000;355(9210):1176-8
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332(15):1004-14
   PubMed Web of Science ®Google Scholar
• Weiss RB, Donehower RC, Wiernik PH, Hypersensitivity reactions from taxol. J Clin Oncol 1990;8(7):1263-8
   PubMed Web of Science ®Google Scholar
• Bookman MA, Kloth DD, Kover PE, Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Semin Oncol 1997;24(6 Suppl 19):S19-3- S-5
   PubMedGoogle Scholar
• Fossella FV, Lee JS, Murphy WK, Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994;12(6):1238-44
   PubMed Web of Science ®Google Scholar
• Markman M, Kennedy A, Webster K, Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000;18(1):102-5
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12(12):2654-66
   PubMed Web of Science ®Google Scholar
• Weiss RB. Hypersensitivity reactions. Semin Oncol 1992;19(5):458-77
   PubMed Web of Science ®Google Scholar
• Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19(4):424-36
   PubMed Web of Science ®Google Scholar
• Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997;54(Suppl 4):30-5
   PubMedGoogle Scholar
• Uziely B, Jeffers S, Isacson R, Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13(7):1777-85
   PubMed Web of Science ®Google Scholar
• Goram AL, Richmond PL. Pegylated liposomal doxorubicin: tolerability and toxicity. Pharmacotherapy 2001;21(6):751-63
   PubMed Web of Science ®Google Scholar
• Peereboom DM, Donehower RC, Eisenhauer EA, Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 1993;11(5):885-90
   PubMed Web of Science ®Google Scholar
• Essayan DM, Kagey-Sobotka A, Colarusso PJ, Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 1996;97(1 Pt 1):42-6
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Szebeni J, Savay S, Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003;14(9):1430-7
   PubMed Web of Science ®Google Scholar
• Dizon DS, Schwartz J, Rojan A, Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. Gynecol Oncol 2006;100(1):149-51
   PubMed Web of Science ®Google Scholar
• Moon C, Verschraegen CF, Bevers M, Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 2000;11(7):565-8
   PubMed Web of Science ®Google Scholar
• Bernstein BJ. Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions. Ann Pharmacother 2000;34(11):1332-5
   PubMed Web of Science ®Google Scholar
• Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 1994;53(1):121-2
   PubMed Web of Science ®Google Scholar
• Robinson JB, Singh D, Bodurka-Bevers DC, Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 2001;82(3):550-8
   PubMed Web of Science ®Google Scholar
• Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006;6(6):476-81
   PubMed Web of Science ®Google Scholar
• Wendel GD Jr, Stark BJ, Jamison RB, Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985;312(19):1229-32
   PubMed Web of Science ®Google Scholar
• Sullivan TJ. Antigen-specific desensitization of patients allergic to penicillin. J Allergy Clin Immunol 1982;69(6):500-8
   PubMed Web of Science ®Google Scholar
• Schwartz LB, Metcalfe DD, Miller JS, Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987;316(26):1622-6
   PubMed Web of Science ®Google Scholar
• Hesterberg PE, Banerji A, Oren E, Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 2009;123(6):1262-7 e1
   PubMed Web of Science ®Google Scholar
• Torres MJ, Blanca M, Fernandez J, Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003;58(10):961-72
   PubMed Web of Science ®Google Scholar
• Chan A, Shih V, Tham Chee K. Liposomal doxorubicin-associated acute hypersensitivity despite appropriate preventive measures. J Oncol Pharm Pract 2007;13(2):105-7
   PubMedGoogle Scholar
• Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol 2005;94(5):575-80
   PubMed Web of Science ®Google Scholar
• Choi J, Harnett P, Fulcher DA. Carboplatin desensitization. Ann Allergy Asthma Immunol 2004;93(2):137-41
   PubMed Web of Science ®Google Scholar
• Confino-Cohen R, Fishman A, Altaras M, Goldberg A. Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer 2005;104(3):640-3
   PubMed Web of Science ®Google Scholar
• Goldberg A, Confino-Cohen R, Fishman A, A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol 1996;98(4):841-3
   PubMed Web of Science ®Google Scholar
• Mis L, Fernando NH, Hurwitz HI, Morse MA. Successful desensitization to oxaliplatin. Ann Pharmacother 2005;39(5):966-9
   PubMed Web of Science ®Google Scholar
• Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005;99(2):393-9
   PubMed Web of Science ®Google Scholar
• Castells MC, Tennant NM, Sloane DE, Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122(3):574-80
   PubMed Web of Science ®Google Scholar
• Stark BJ, Earl HS, Gross GN, Acute and chronic desensitization of penicillin-allergic patients using oral penicillin. J Allergy Clin Immunol 1987;79:523-32
   PubMed Web of Science ®Google Scholar
• Demoly P, Bousquet J. Drug allergy diagnosis work up. Allergy 2002;57(Suppl 72):37-40
   PubMedGoogle Scholar
• Simons FE, Frew AJ, Ansotegui IJ, Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 2007;120(1 Suppl):S2-24
   PubMed Web of Science ®Google Scholar
• Simons FE. 9. Anaphylaxis. J Allergy Clin Immunol 2008;121(2 Suppl):S402-7; quiz S20
   PubMed Web of Science ®Google Scholar
• Balsari A, Lombardo N, Ghione M. Skin and perivascular toxicity induced experimentally by doxorubicin. J Chemother 1989;1(5):324-9
   PubMed Web of Science ®Google Scholar
• Gruchalla RS. Acute drug desensitization. Clin Exp Allergy 1998;28(Suppl 4):63-4
   PubMedGoogle Scholar
• Jones R, Ryan M, Friedlander M. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecol Oncol 2003;89(1):112-5
   PubMed Web of Science ®Google Scholar
• Markman M, Zanotti K, Kulp B, Peterson G. Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol 2003;89(3):514-6
   PubMed Web of Science ®Google Scholar
• Grosen E, Siitari E, Larrison E, Paclitaxel hypersensitivity reactions related to bee-sting allergy. Lancet 2000;355(9200):288-9
   PubMed Web of Science ®Google Scholar
• Newman Taylor AJ, Cullinan P, Lympany PA, Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. Am J Respir Crit Care Med 1999;160(2):435-8
   PubMed Web of Science ®Google Scholar
• Castells M. Drug desensitization in oncology: chemotherapy agents and monoclonal antibodies. In: WJ Pichler, editor, Drug hypersensitivity. 1st edition. New York: Karger; 2007. p. 413-25
   Google Scholar
• Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90(4):300-6
   PubMed Web of Science ®Google Scholar
• Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 1999;162(11):6811-8
   PubMed Web of Science ®Google Scholar
• Perera PY, Mayadas TN, Takeuchi O, CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol 2001;166(1):574-81
   PubMed Web of Science ®Google Scholar
• Skubitz KM, Skubitz AP. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 1998;9(1):45-50
   PubMed Web of Science ®Google Scholar
• Nozawa H, Muto Y, Yamada Y. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer. Clin Ther 2008;30(6):1160-5
   PubMed Web of Science ®Google Scholar
• Castells M. Rapid desensitization for hypersensitivity reactions to chemotherapy agents. Curr Opin Allergy Clin Immunol 2006;6(4):271-7
   PubMed Web of Science ®Google Scholar